These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Comparable survival in ischemic and nonischemic cardiomyopathy secondary to ventricular tachyarrhythmias and aborted cardiac arrest. Rusnak J; Behnes M; Schupp T; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Ansari U; El-Battrawy I; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I Coron Artery Dis; 2019 Jun; 30(4):303-311. PubMed ID: 30896453 [TBL] [Abstract][Full Text] [Related]
25. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction. Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203 [TBL] [Abstract][Full Text] [Related]
26. Indications for an implantable cardioverter defibrillator (ICD). Aizawa Y; Chinushi M; Washizuka T Intern Med; 2004 May; 43(5):360-7. PubMed ID: 15206546 [TBL] [Abstract][Full Text] [Related]
27. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. Kutyifa V; Vermilye K; Daimee UA; McNitt S; Klein H; Moss AJ Europace; 2018 Sep; 20(FI2):f225-f232. PubMed ID: 29905788 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195 [TBL] [Abstract][Full Text] [Related]
29. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy. Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421 [TBL] [Abstract][Full Text] [Related]
30. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation. Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988 [TBL] [Abstract][Full Text] [Related]
31. Microvolt T-wave alternans and autonomic nervous system parameters can be helpful in the identification of low-arrhythmic risk patients with ischemic left ventricular systolic dysfunction. Daniłowicz-Szymanowicz L; Kaufmann D; Rozwadowska K; Kempa M; Lewicka E; Raczak G PLoS One; 2018; 13(5):e0196812. PubMed ID: 29723261 [TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Weidner K; Behnes M; Schupp T; Rusnak J; Reiser L; Taton G; Reichelt T; Ellguth D; Engelke N; Bollow A; El-Battrawy I; Ansari U; Hoppner J; Nienaber CA; Mashayekhi K; Weiß C; Akin M; Borggrefe M; Akin I Clin Res Cardiol; 2019 Jun; 108(6):669-682. PubMed ID: 30578436 [TBL] [Abstract][Full Text] [Related]
33. Electrocardiographic parameters effectively predict ventricular tachycardia/fibrillation in acute phase and abnormal cardiac function in chronic phase of ST-segment elevation myocardial infarction. Yu Z; Chen Z; Wu Y; Chen R; Li M; Chen X; Qin S; Liang Y; Su Y; Ge J J Cardiovasc Electrophysiol; 2018 May; 29(5):756-766. PubMed ID: 29399929 [TBL] [Abstract][Full Text] [Related]
34. Time-dependent effect of cardiac resynchronization therapy on ventricular repolarization and ventricular arrhythmias. Itoh M; Yoshida A; Fukuzawa K; Kiuchi K; Imamura K; Fujiwara R; Suzuki A; Nakanishi T; Yamashita S; Matsumoto A; Hirata K Europace; 2013 Dec; 15(12):1798-804. PubMed ID: 23736809 [TBL] [Abstract][Full Text] [Related]
36. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259 [TBL] [Abstract][Full Text] [Related]
37. Lifelong arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy: distribution of events and impact of periodical reassessment. Cappelletto C; Stolfo D; De Luca A; Pinamonti B; Barbati G; Pivetta A; Gobbo M; Brun F; Merlo M; Sinagra G Europace; 2018 Jun; 20(FI1):f20-f29. PubMed ID: 28633348 [TBL] [Abstract][Full Text] [Related]
38. OptiVol fluid index: does an association with ventricular arrhythmias hold water? Sullivan RM; Olshansky B J Cardiovasc Electrophysiol; 2011 Mar; 22(3):300-1. PubMed ID: 21091968 [No Abstract] [Full Text] [Related]
39. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]